The Chief Executive of the China Spinal Cord Injury Network (CSCIN), Dr Wise Young, has announced that stem-cell therapy trials have shown very significant results in helping immobile patients to become mobile again.  Following the second round of tests that use stem cells to regrow nerve fibres, the CSCIN has applied for regulatory approval in China for a third and final phase, which…

The much-anticipated public consultation on "Healthcare Finance Reform" to be launched on the second half of this year is starting to generate attention towards some of the main issues to be addressed, among which is the possibility of the Hong Kong Government implementing a company to provide medical insurance for cases where private insurers may not be able to provide a "reasonable cover" to policyholders.